Clinical Trial Update: OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction [Phase 3]

View source ↗

Summary

Phase 3 trial (OASIS-6) evaluated fondaparinux versus control therapy in patients with ST-elevation myocardial infarction and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• St-elevation Myocardial Infarction

Drugs mentioned

• ARIXTRA (fondaparinux sodium)
• Unfractionated Heparin (unfractionated heparin)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Thromboembolism | Phase 3 | Status: COMPLETED